Pfizer Inc. (NYSE:PFE) Shares Purchased by Metis Global Partners LLC

Metis Global Partners LLC lifted its holdings in Pfizer Inc. (NYSE:PFE) by 16.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 304,749 shares of the biopharmaceutical company’s stock after purchasing an additional 42,083 shares during the period. Metis Global Partners LLC’s holdings in Pfizer were worth $8,774,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Briaud Financial Planning Inc acquired a new position in shares of Pfizer in the 3rd quarter worth $30,000. GoalVest Advisory LLC boosted its stake in Pfizer by 304.9% in the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 811 shares during the period. Mizuho Securities Co. Ltd. purchased a new position in Pfizer during the 3rd quarter worth approximately $34,000. VisionPoint Advisory Group LLC raised its stake in Pfizer by 52,350.0% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 1,047 shares during the period. Finally, Tennessee Valley Asset Management Partners purchased a new stake in shares of Pfizer in the fourth quarter valued at $36,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms recently weighed in on PFE. Argus lowered Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Guggenheim assumed coverage on shares of Pfizer in a research report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price target for the company. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research report on Monday, April 15th. Morgan Stanley increased their target price on shares of Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research report on Thursday. Finally, BMO Capital Markets restated an “outperform” rating and set a $36.00 price target (up from $33.00) on shares of Pfizer in a report on Thursday. Eleven investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $36.00.

Pfizer Stock Performance

Shares of NYSE:PFE traded up $0.11 during trading on Friday, reaching $27.81. The stock had a trading volume of 60,568,852 shares, compared to its average volume of 41,900,304. The stock has a fifty day simple moving average of $26.88 and a two-hundred day simple moving average of $28.16. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69. Pfizer Inc. has a 52 week low of $25.20 and a 52 week high of $40.37. The firm has a market capitalization of $157.48 billion, a price-to-earnings ratio of -463.42, a P/E/G ratio of 1.19 and a beta of 0.63.

Pfizer (NYSE:PFE) last announced its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 EPS for the quarter, topping the consensus estimate of $0.56 by $0.26. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.58%. The firm had revenue of $14.88 billion for the quarter, compared to the consensus estimate of $13.87 billion. During the same quarter last year, the firm posted $1.23 EPS. The business’s quarterly revenue was down 19.5% on a year-over-year basis. As a group, analysts anticipate that Pfizer Inc. will post 2.39 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 10th will be issued a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a yield of 6.04%. The ex-dividend date of this dividend is Thursday, May 9th. Pfizer’s dividend payout ratio (DPR) is currently -2,799.53%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.